Adrenergic beta-agonist: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: {{subpages}} '''Adrenergic beta-agonists''' ('''LABA''') are "drugs that selectively bind to and activate beta-adrenergic receptors."<ref>{{MeSH}}</ref> ==Medical uses== ===Asthma=== ...) |
imported>Robert Badgett No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
'''Adrenergic beta-agonists''' (''' | '''Adrenergic beta-agonists''' ('''beta-agonists''') are "drugs that selectively bind to and activate beta-[[adrenergic receptor]]s."<ref>{{MeSH}}</ref> | ||
==Medical uses== | ==Medical uses== | ||
| Line 8: | Line 8: | ||
:''See [[chronic obstructive pulmonary disease]]'' | :''See [[chronic obstructive pulmonary disease]]'' | ||
Among patients with COPD, reduction in mortality may not occur unless LABAs are combined with [[corticosteroid]]s.<ref name="pmid18460518">{{cite journal |author=Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R |title=Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review |journal=Chest |volume=133 |issue=5 |pages=1079–87 |year=2008 |month=May |pmid=18460518 |doi=10.1378/chest.07-1167 |url=http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=18460518 |issn=}}</ref> | Among patients with COPD, reduction in mortality may not occur unless LABAs are combined with [[corticosteroid]]s.<ref name="pmid18460518">{{cite journal |author=Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R |title=Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review |journal=Chest |volume=133 |issue=5 |pages=1079–87 |year=2008 |month=May |pmid=18460518 |doi=10.1378/chest.07-1167 |url=http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=18460518 |issn=}}</ref> | ||
==Drug toxicity== | |||
Long acting adrenergic beta-agonists (LABA) associated with may adverse outcomes among patients with ''asthma'' when used ''without'' [[corticosteroid]]s and maybe among African American patients.<ref name="pmid16754916">{{cite journal |author=Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE |title=Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths |journal=Ann. Intern. Med. |volume=144 |issue=12 |pages=904-12 |year=2006 |pmid=16754916 |doi= |url=http://www.annals.org/cgi/pmidlookup?view=reprint&pmid=16754916 |issn=}}</ref> They might be safe in asthma as long as [[corticosteroid]]s are used. According to a [[meta-analysis]] by the [[Cochrane Collaboration]], when used ''with'' [[corticosteroid]]s the relative risk for asthma-related death is increased at 1.34 although this increase was not statistically significant with a [[confidence interval]] of 0.30 to 5.97.<ref name="pmid17253458">{{cite journal |author=Walters EH, Gibson PG, Lasserson TJ, Walters JA |title=Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid |journal=Cochrane Database Syst Rev |volume= |issue=1 |pages=CD001385 |year=2007 |pmid=17253458 |doi=10.1002/14651858.CD001385.pub2 |url=http://dx.doi.org/10.1002/14651858.CD001385.pub2 |issn=}}</ref> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 21:12, 19 August 2008
Adrenergic beta-agonists (beta-agonists) are "drugs that selectively bind to and activate beta-adrenergic receptors."[1]
Medical uses
Asthma
- See asthma
Chronic obstructive pulmonary disease
Among patients with COPD, reduction in mortality may not occur unless LABAs are combined with corticosteroids.[2]
Drug toxicity
Long acting adrenergic beta-agonists (LABA) associated with may adverse outcomes among patients with asthma when used without corticosteroids and maybe among African American patients.[3] They might be safe in asthma as long as corticosteroids are used. According to a meta-analysis by the Cochrane Collaboration, when used with corticosteroids the relative risk for asthma-related death is increased at 1.34 although this increase was not statistically significant with a confidence interval of 0.30 to 5.97.[4]
References
- ↑ Anonymous (2024), Adrenergic beta-agonist (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R (May 2008). "Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review". Chest 133 (5): 1079–87. DOI:10.1378/chest.07-1167. PMID 18460518. Research Blogging.
- ↑ Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE (2006). "Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths". Ann. Intern. Med. 144 (12): 904-12. PMID 16754916. [e]
- ↑ Walters EH, Gibson PG, Lasserson TJ, Walters JA (2007). "Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid". Cochrane Database Syst Rev (1): CD001385. DOI:10.1002/14651858.CD001385.pub2. PMID 17253458. Research Blogging.